Blueprint Medicines Corporation (0HOJ.L)
USD 97.85
(1.4%)
USD 97.85
(1.4%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -486.27 Million USD | 11.47% |
| 2022 | -549.25 Million USD | 15.3% |
| 2021 | -648.46 Million USD | -314.62% |
| 2020 | 302.14 Million USD | 182.42% |
| 2019 | -366.58 Million USD | -48.4% |
| 2018 | -247.02 Million USD | -65.26% |
| 2017 | -149.47 Million USD | -103.07% |
| 2016 | -73.6 Million USD | -38.83% |
| 2015 | -53.02 Million USD | -33.11% |
| 2014 | -39.83 Million USD | -91.74% |
| 2013 | -20.77 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -48.97 Million USD | -13.77% |
| 2024 Q1 | -78.82 Million USD | 25.01% |
| 2024 Q2 | -43.04 Million USD | 45.39% |
| 2023 Q4 | -105.11 Million USD | 18.51% |
| 2023 FY | -486.27 Million USD | 11.47% |
| 2023 Q1 | -135.37 Million USD | 13.67% |
| 2023 Q2 | -127.98 Million USD | 5.46% |
| 2023 Q3 | -128.98 Million USD | -0.78% |
| 2022 Q1 | -105.8 Million USD | 66.52% |
| 2022 FY | -549.25 Million USD | 15.3% |
| 2022 Q2 | -157.63 Million USD | -48.99% |
| 2022 Q4 | -156.81 Million USD | -26.18% |
| 2022 Q3 | -124.27 Million USD | 21.16% |
| 2021 Q4 | -316.05 Million USD | -169.91% |
| 2021 Q1 | -100.23 Million USD | -16.6% |
| 2021 Q2 | -108.51 Million USD | -8.25% |
| 2021 Q3 | -117.09 Million USD | -7.91% |
| 2021 FY | -648.46 Million USD | -314.62% |
| 2020 FY | 302.14 Million USD | 182.42% |
| 2020 Q4 | -85.96 Million USD | -113.57% |
| 2020 Q3 | 633.36 Million USD | 606.54% |
| 2020 Q2 | -125.03 Million USD | -10.01% |
| 2020 Q1 | -113.65 Million USD | -63.82% |
| 2019 Q2 | -103.91 Million USD | -15.37% |
| 2019 Q3 | -97.96 Million USD | 5.73% |
| 2019 Q4 | -69.37 Million USD | 29.18% |
| 2019 FY | -366.58 Million USD | -48.4% |
| 2019 Q1 | -90.07 Million USD | -8.34% |
| 2018 Q1 | -58.91 Million USD | -17.6% |
| 2018 Q2 | -29.46 Million USD | 49.98% |
| 2018 Q3 | -75.5 Million USD | -156.25% |
| 2018 Q4 | -83.14 Million USD | -10.11% |
| 2018 FY | -247.02 Million USD | -65.26% |
| 2017 Q3 | -38.61 Million USD | -12.85% |
| 2017 Q2 | -34.21 Million USD | -20.77% |
| 2017 Q1 | -28.33 Million USD | -32.55% |
| 2017 FY | -149.47 Million USD | -103.07% |
| 2017 Q4 | -50.09 Million USD | -29.74% |
| 2016 Q4 | -21.37 Million USD | -26.59% |
| 2016 Q3 | -16.88 Million USD | 10.65% |
| 2016 Q2 | -18.89 Million USD | -22.5% |
| 2016 FY | -73.6 Million USD | -38.83% |
| 2016 Q1 | -15.42 Million USD | -0.03% |
| 2015 Q3 | -12.47 Million USD | -0.65% |
| 2015 FY | -53.02 Million USD | -33.11% |
| 2015 Q2 | -12.39 Million USD | -9.22% |
| 2015 Q4 | -15.42 Million USD | -23.59% |
| 2015 Q1 | -11.35 Million USD | 20.6% |
| 2014 FY | -39.83 Million USD | -91.74% |
| 2014 Q1 | -6.95 Million USD | 0.0% |
| 2014 Q3 | -10.28 Million USD | -25.49% |
| 2014 Q4 | -14.29 Million USD | -38.93% |
| 2014 Q2 | -8.19 Million USD | -17.92% |
| 2013 FY | -20.77 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -169.18 Million USD | -187.43% |
| Dynavax Technologies Corporation | -37.02 Million USD | -1213.268% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -9129.019% |
| Perrigo Company plc | 151.9 Million USD | 420.13% |
| Illumina, Inc. | -1.06 Billion USD | 54.511% |
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 107.09% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | -5.584% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 96.545% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 124.597% |
| Heron Therapeutics, Inc. | -110.61 Million USD | -339.612% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 112.015% |
| Unity Biotechnology, Inc. | -44.66 Million USD | -988.672% |
| Waters Corporation | 817.67 Million USD | 159.471% |
| Biogen Inc. | 1.29 Billion USD | 137.498% |
| Sangamo Therapeutics, Inc. | -274 Million USD | -77.47% |
| Evolus, Inc. | -49.23 Million USD | -887.705% |
| Adicet Bio, Inc. | -152.03 Million USD | -219.839% |
| Cara Therapeutics, Inc. | -121.49 Million USD | -300.244% |
| bluebird bio, Inc. | -244.26 Million USD | -99.08% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | -212.592% |
| FibroGen, Inc. | -281.81 Million USD | -72.552% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 136.021% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | -978.762% |
| Homology Medicines, Inc. | -48.25 Million USD | -907.724% |
| Geron Corporation | -193.94 Million USD | -150.731% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | -72.332% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | -561.655% |
| Myriad Genetics, Inc. | -123.7 Million USD | -293.11% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -382.288% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 5.631% |
| Zoetis Inc. | 3.06 Billion USD | 115.845% |
| Abeona Therapeutics Inc. | -48.2 Million USD | -908.873% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 144.724% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 350.09% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 111.289% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | -1141.992% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | -37.471% |
| Atara Biotherapeutics, Inc. | -276 Million USD | -76.183% |
| Verastem, Inc. | -92.08 Million USD | -428.08% |
| Nektar Therapeutics | -137.42 Million USD | -253.849% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | -109.76% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | -399.478% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | -81.566% |
| OPKO Health, Inc. | -157.02 Million USD | -209.689% |
| Exelixis, Inc. | 170.88 Million USD | 384.564% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 293.813% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 553.27% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -772.152% |
| uniQure N.V. | -282.87 Million USD | -71.908% |
| Imunon, Inc. | -21.03 Million USD | -2212.254% |
| Insmed Incorporated | -709.62 Million USD | 31.474% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 244.05% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | -24.213% |
| TG Therapeutics, Inc. | 20.63 Million USD | 2456.793% |
| Incyte Corporation | 620.52 Million USD | 178.365% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 33.057% |